QDEL QUIDEL CORP

Quidel and World Champion Los Angeles Rams Partner to Combat COVID-19 and Promote Health Awareness in the L.A. Community

Quidel Corporation (“Quidel”), a subsidiary of QuidelOrtho Corporation (NASDAQ: QDEL) and a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and the World Champion Los Angeles Rams today announced a multi-year partnership agreement to promote health awareness and COVID-19 testing. The agreement makes Quidel an “Official Partner of the Los Angeles Rams” and designates Quidel’s QuickVue at-home rapid antigen test as the “Official At-Home COVID Test of the Los Angeles Rams.” In addition, the partnership includes a variety of promotions and stadium activation initiatives as well as a presence at community programs across the greater Los Angeles area.

This press release features multimedia. View the full release here:

"As a leading diagnostics company founded and headquartered in Southern California, Quidel is proud to be an official partner of the Los Angeles Rams," said Douglas Bryant, Chairman and CEO of QuidelOrtho. "It is an honor to work close to home and with a winning organization whose dedication to community service matches our own. We look forward to teaming up to promote health awareness and the benefits of COVID-19 testing."

“As we prepare to kick off our season and defend our championship, we are pleased to welcome Quidel to the Rams family,” said Rams Chief Commercial Officer Jen Prince. “Quidel’s history in Southern California and commitment to health and wellness make them a great fit to help enhance gamedays and our community events year-round.”

Mr. Bryant noted, “With our 10-minute QuickVue rapid antigen test taking the field as the ‘Official At-Home COVID Test of the Los Angeles Rams,’ we will work with the Rams organization to champion the message of easy and accessible at-home COVID-19 testing at the stadium and further communicate the importance of testing to all communities through Rams radio, television, and digital programming.”

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.

Ranked among the world’s largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint in clinical labs and transfusion medicine.

Our company’s comprehensive product portfolio delivers accuracy, speed, automation, and access, providing critical information when and where it is needed most. Inspired by a spirit of service, the QuidelOrtho family is committed to enhancing the well-being of people worldwide and happy in the knowledge we are making a difference. For more information, please visit .

EN
01/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUIDEL CORP

 PRESS RELEASE

QuidelOrtho® Introduces Results Manager™ System

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. This press release features multimedia. View the full release here: QuidelOrtho® Results Manager™ System (Graphic: Business Wire) The Quid...

 PRESS RELEASE

QuidelOrtho to Participate in the 46th Annual Raymond James Institutio...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of QuidelOrtho’s management team will participate in a presentation at 8:40 a.m. ET / 5:40 a.m. PT. Interested parties can access the live webcast and replay in the “Events & Presentations” section ...

 PRESS RELEASE

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Result...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 29, 2024. “We are pleased with our 2024 business performance and ended the year with positive momentum leading into 2025,” said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. “The growth of our underlying business with its recurring revenue busin...

 PRESS RELEASE

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. Fourth Quarter 2024 Preliminary Unaudited Revenues The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately $702 million to $707 million, which would be in line with its previously announced 2024 financia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch